Regardless of these historic approvals, GSK’s supremacy within the unexplored RSV vaccine space is threatened by Pfizer, which is aggressively pursuing market share for its personal RSV vaccine Abrysvo (
), in response to analysis by GlobalData, a significant information and analytics agency.
Arexvy’s First-Mover Benefit in RSV Vaccines
“Whereas Arexvy was first to achieve US approval, which marked the primary time a vaccine was authorised to be used in opposition to RSV in any inhabitants, wherever on the planet, Pfizer’s Abrysvo was accredited by the FDA shortly after, permitting enough time for each vaccines to be accessible for US launch across the identical time this fall, earlier than the winter RSV season,” mentioned Nancy Jaser, Pharma Analyst at GlobalData, in an announcement.
“Due to this fact, GSK isn’t more likely to expertise a major first-mover benefit for market share within the US. Nevertheless, Arexvy should profit from a first-mover benefit within the EU as Pfizer’s Abrysvo has but to achieve approval to be used by the EC. A choice is predicted later this 12 months,” Jaser added.
Pfizer’s Abrysvo May very well be a Main RSV Vaccine
Whereas each vaccines confirmed wonderful efficacy in pivotal research, Pfizer’s vaccine has a major edge over Arexvy. Abrysvo is now being evaluated in the US as a maternal vaccine to guard newborns in opposition to RSV at beginning. In response to the report, the FDA’s Vaccines Advisory Committee voted in favor of recommending Abrysvo as a maternal RSV vaccination.
Moderna’s RSV vaccine, mRNA-1345, is predicted to pose extra competitors. Constructive Section III information in older adults have been launched in January, and Moderna plans to use for US clearance within the first half of 2023.
“Abrysvo will seemingly be the primary accredited RSV vaccine to guard infants worldwide, probably resulting in a better market share than its rivals. It’s at present the one vaccine candidate in late-stage growth that targets a number of affected person segments,” Jaser mentioned.
- FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine – (https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine)
- FDA Approves Pfizer RSV Vaccine: URMC Researchers at Middle of Improvement – (https://www.urmc.rochester.edu/information/story/race-to-rsv-vaccine-approval-urmc-researchers-leading-the-way)